Talk to Robyn

00 1 718 213 49 04

Search inside this page

Publishers

All regions

Free Market Research Guides to Download

Pathology Analysis & Statistics, February 2013 (p4)

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

91-130 of about 4 900 reports
Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Brivaracetam (Epilepsy) - Forecast and Market Analysis to 2022?. ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United States, World, Europe, United Kingdom
Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Ganaxolone (Epilepsy) - Forecast and Market Analysis to 2022?. ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United States, World, Europe, United Kingdom
Vimpat (Epilepsy) - Forecast and Market Analysis to 2022

Vimpat (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Vimpat (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Vimpat (Epilepsy) - Forecast and Market Analysis to 2022?. Epilepsy ...

  • Industries : Pathology
  • Countries : United States, Spain, Italy, France, Germany, Japan, India, World, Europe, United Kingdom
Fycompa (Epilepsy) - Forecast and Market Analysis to 2022

Fycompa (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Fycompa (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Fycompa (Epilepsy) - Forecast and Market Analysis to 2022?. Epilepsy ...

  • Industries : Pathology
  • Countries : Japan, United States, Spain, Italy, France, Germany, World, Europe, United Kingdom
VX-765 (Epilepsy) - Forecast and Market Analysis to 2022

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

VX-765 (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?VX-765 (Epilepsy) - Forecast and Market Analysis to 2022?. Epilepsy ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United States, World, Europe, United Kingdom
Zebinix (Epilepsy) - Forecast and Market Analysis to 2022

Zebinix (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Zebinix (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Zebinix (Epilepsy) - Forecast and Market Analysis to 2022?. Epilepsy ...

  • Industries : Pathology
  • Countries : United States, Spain, Italy, France, Germany, India, World, Europe, United Kingdom
Banzel / Inovelon (Epilepsy) - Forecast and Market Analysis to 2022

Banzel / Inovelon (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Banzel / Inovelon (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Banzel / Inovelon (Epilepsy) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : World, Spain, Italy, France, Germany, Japan, United States, Europe, United Kingdom
Zonegran (Epilepsy) - Forecast and Market Analysis to 2022

Zonegran (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Zonegran (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Zonegran (Epilepsy) - Forecast and Market Analysis to 2022?. Epilepsy ...

  • Industries : Pathology
  • Countries : Japan, United States, World, Spain, Italy, France, Germany, India, Europe, United Kingdom, China
Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis to 2022

Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2013
  • by Global Data

Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, ?Trobalt/Potiga (Epilepsy) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : United States
Hemoglobin A1c Testing Markets

Hemoglobin A1c Testing Markets

  • $ 3 400
  • Industry report
  • March 2013
  • by TriMark Publications

Hemoglobin A1c (HbA1c) testing is the most recent major technology to have entered the diabetes testing market. As the global prevalence of diabetes mellitus continues to increase rapidly, with more than ...

  • Industries : Pathology
  • Countries : United States, World
PharmaPoint: Epilepsy - Current and Future Players

PharmaPoint: Epilepsy - Current and Future Players

  • $ 2 995
  • Industry report
  • February 2013
  • by Global Data

PharmaPoint: Epilepsy - Current and Future Players Summary GlobalData has released its pharma report, ?PharmaPoint: Epilepsy - Current and Future Players?. The report is a vital source of up-to-date ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Osteoporosis - Current and Future Players

PharmaPoint: Osteoporosis - Current and Future Players

  • $ 2 995
  • Industry report
  • February 2013
  • by Global Data

PharmaPoint: Osteoporosis - Current and Future Players Summary Osteoporosis is caused by the gradual weakening of the bones due to abnormal osteocyte function, which occurs as a result of hormonal fluctuations, ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players

PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players

  • $ 2 995
  • Industry report
  • May 2013
  • by Global Data

PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players Summary GlobalData has released its pharma report, ?PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players?. ...

  • Industries : Pathology
  • Countries : World
PharmaPoint: Multiple Sclerosis - Current and Future Players

PharmaPoint: Multiple Sclerosis - Current and Future Players

  • $ 2 995
  • Industry report
  • March 2013
  • by Global Data

PharmaPoint: Multiple Sclerosis - Current and Future Players Summary GlobalData has released its pharma report, ?PharmaPoint: Multiple Sclerosis - Current and Future Players?. The report is a vital source ...

  • Industries : Pathology
  • Countries : World
Therapy in United States: Type 2 Diabetes - Pipeline Review, H1 2012

Therapy in United States: Type 2 Diabetes - Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • March 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Type 2 Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

  • Industries : Pathology
Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013

Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013

  • $ 2 500
  • Industry report
  • February 2013
  • by Global Data

Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, ?Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, ...

  • Industries : Pathology
  • Countries : World
Pathology Industry: Non-Small Cell Lung Cancer - Pipeline Review, H1 2012

Pathology Industry: Non-Small Cell Lung Cancer - Pipeline Review, H1 2012

  • $ 2 500
  • Industry report
  • February 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...

  • Industries : Pathology
  • Countries : United States, World
Rheumatoid Arthritis - Pipeline Review, H1 2013

Rheumatoid Arthritis - Pipeline Review, H1 2013

  • $ 2 500
  • Company report
  • March 2013
  • by Global Markets Direct

Rheumatoid Arthritis - Pipeline Review, H1 2013 Summary Global Markets Direct's, 'Rheumatoid Arthritis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This ...

  • Industries : Pathology
Drug and Medication Industry: Prostate Cancer - Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer - Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • March 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

  • Industries : Pathology
  • Countries : United States
Drug and Medication Industry: Ovarian Cancer - Pipeline Review, H1 2012

Drug and Medication Industry: Ovarian Cancer - Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

  • Industries : Pathology
  • Countries : United States
Pathology in United States: Breast Cancer - Pipeline Review, H1 2012

Pathology in United States: Breast Cancer - Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

  • Industries : Pathology
Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013

  • $ 2 500
  • Industry report
  • March 2013
  • by Global Data

Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, ?Attention Deficit Hyperactivity Disorder (ADHD) Global Clinical Trials ...

  • Industries : Pathology
  • Countries : World, United States
World Pathology: Metastatic Lung Cancer - Pipeline Review, H1 2012

World Pathology: Metastatic Lung Cancer - Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

  • Industries : Pathology
  • Countries : World, United States, Canada
World Pathology: Interstitial Cystitis (Painful Bladder Syndrome) ? Pipeline Review, H1 2012

World Pathology: Interstitial Cystitis (Painful Bladder Syndrome) ? Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. ...

  • Industries : Pathology
  • Countries : World
World Pathology: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) ? Pipeline Review, H1 2012

World Pathology: Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) ? Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with latest updates, and special features on late-stage and ...

  • Industries : Pathology
  • Countries : World
World Pathology: Chronic Plaque Psoriasis - Pipeline Review, H1 2012

World Pathology: Chronic Plaque Psoriasis - Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

  • Industries : Pathology
  • Countries : World
Pathology in United States: Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2012

Pathology in United States: Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

  • Industries : Pathology
  • Countries : United States
Pathology in United States: Post-Traumatic Stress Disorder (PTSD) ? Pipeline Review, H1 2012

Pathology in United States: Post-Traumatic Stress Disorder (PTSD) ? Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews ...

  • Industries : Pathology
  • Countries : United States, World
World Pathology: Waldenstrom Macroglobulinemia - Pipeline Review, H1 2012

World Pathology: Waldenstrom Macroglobulinemia - Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...

  • Industries : Pathology
  • Countries : United States, World
Therapy in United States: Post Menopausal Osteoporosis - Pipeline Review, H1 2012

Therapy in United States: Post Menopausal Osteoporosis - Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2013
  • by Global Markets Direct

This report provides data on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key ...

  • Industries : Pathology
  • Countries : World

Norway Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Norway

Austria Peptic Ulcer Disease, 45-59 Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Austria

Iraq Prostate Cancer, 45-59 Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Iraq, World

Lesotho Post-traumatic Stress Disorder, 15-29 Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Lesotho

Palau Post-traumatic Stress Disorder, 45-59 Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : World

Honduras Prostate Cancer, 70+ Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Honduras

Papua New Guinea Schistosomiasis, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Papua New Guinea, Guinea

Paraguay Prostate Cancer, 70+ Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Paraguay

Dominican Republic Post-traumatic Stress Disorder, 30-44 Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Dominican Republic, Dominica

Belgium Protein-energy Malnutrition, 70+ Yrs, Male, Dalys

  • $ 250
  • Industry data
  • May 2013

Yearly, From 2005 To 2030
By Business Monitor International
Source: WHO, World Bank, IMF, BMI research

  • Industries : Pathology
  • Countries : Belgium

» Download Public Reports

About 17 000 reports
Company Report: Pathology in The United States and Ireland for Year 2013

Company Report: Pathology in The United States and Ireland for Year 2013

  • Company report
  • May 2013
  • 5 pages
  • by Corporation

... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...


» Read our Company Profiles

About 200 Companies

GlaxoSmithKline P.L.C.

United States

Novartis Inc.

Switzerland

GlaxoSmithKline PLC

United Kingdom

Eli Lilly and Co.

United States

Lilly and Co.

United States

Privacy Policy by TRUSTe
ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.